Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...

A 3-hour WHO Hantavirus emergency Zoom call was held this morning, providing outbreak analysis. It seemed that for every ...

Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism ...

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.

Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...

Myocardial infarction (MI) and subsequent ischemia-reperfusion injury trigger a devastating cascade of oxidative stress and cardiomyocyte death, ...

Welcome to cbdMD Inc.'s March 31, 2026, Second Fiscal Quarter of 2026 Earnings Call and Update. This afternoon, the company issued a press release that provided an overview of its first quarter ...

Breakout Momentum Plays You Need to Know About Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, ...

A new nanotechnology treatment reversed Alzheimer’s symptoms in mice by restoring the brain’s natural cleanup system. The specially engineered nanoparticles helped clear toxic amyloid proteins from ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a ...

Japan has spent fifteen years diversifying away from Chinese rare earths—but its longtime aid recipient and economic partner ...